Trial Profile
Efficacy and Safety of Sofosbuvir Plus Daclatasvir in Chinese Treatment-experienced Patients With Chronic Genotype 1b HCV Infection
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 21 Mar 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 16 Mar 2018 Status changed from recruiting to completed.
- 15 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 15 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.